Results 151 to 160 of about 14,700 (205)

Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease

, 2006
Wei‐Qiang Gao, Patricia J. Anderson, Elaine M. Majerus, Elodee A. Tuley, J. Evan Sadler   +4 more
openalex   +1 more source

ADAMTS13 activity and inhibitor [PDF]

, 2008
Adriana M. Doldan-Silvero, Carlos Rodrigo Acevedo-Gadea, Clandine Habib, Jonathan Freeman, Vandita Johari   +4 more
openalex   +1 more source

Agents of shield: glycans mask antibody epitopes on ADAMTS13. [PDF]

Blood Adv
Kretz CA.
europepmc   +1 more source

Severe Plasmodium Falciparum Malaria Is Associated with Circulating Ultra-Large Von Willebrand Multimers and ADAMTS13 Inhibition [PDF]

, 2008
Deirdre Larkin, Vince Jenkins, James Bunn, Alister Craig, Roger J. S. Preston, Cynthia Donkor, George E Grau, Jan A. van Mourik, James S. O’Donnell   +8 more
openalex   +1 more source

Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS. [PDF]

Blood Adv
Bonnez Q, Legan ER, Pareyn I, Boudry F, Anckaert J, Tersteeg C, De Meyer SF, Li R, Vanhoorelbeke K.   +8 more
europepmc   +1 more source

Prospective Study of ADAMTS13 and von Willebrand Factor's Role in the Prediction of Outcomes in Acute Ischemic Stroke. [PDF]

J Clin Med
Makris M, Gavriilaki E, Ztriva E, Evangelidis P, Lefkou E, Vlachaki E, Bountola S, Perifanis V, Matsagkas M, Savopoulos C, Kaiafa G.   +10 more
europepmc   +1 more source

ADAMTS13

, 2006
Yoshihiro FUJIMURA
openalex   +2 more sources

Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor [PDF]

, 2009
Masashi Akiyama, Soichi Takeda, Koichi Kokame, Junichi Takagi, Toshiyuki Miyata   +4 more
openalex   +1 more source

N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP. [PDF]

Blood Adv
Postmus T, Schilder N, Ferreira de Santana J, Langerhorst P, Kaijen P, Coppo P, Joly BS, Veyradier A, Vanhoorelbeke K, Voorberg J.   +9 more
europepmc   +1 more source

Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy. [PDF]

Ann Hematol
Tanaka H, Sakai K, Tamura S, Shiwaku H, Nakamura J, Ueda Y, Bamba S, Nishikubo M, Nagai Y, Matsumoto M.   +9 more
europepmc   +1 more source